What is the primary therapeutic use of Brilinta (ticagrelor)?

A. To treat hyperlipidemia: Brilinta does not lower cholesterol or alter lipid pathways. Hyperlipidemia requires medications that directly modify lipid metabolism, such as statins. Using Brilinta for this purpose would leave the lipid disorder untreated. B. To prevent thrombotic events in patients with acute coronary syndrome: Brilinta inhibits the P2Y12 receptor on platelets, reducing aggregation and decreasing the likelihood of clot formation. This protects against stent thrombosis and recurrent myocardial infarction in ACS patients. It is routinely paired with aspirin as part of dual antiplatelet therapy. C. To manage hypertension: Brilinta has no effect on vascular resistance, cardiac output, or renal sodium handling, which are the main targets of antihypertensive therapy. Blood pressure control relies on medications such as ACE inhibitors, beta blockers, or diuretics. D. As a first-line treatment for heart failure: Brilinta does not improve myocardial function or counteract the neurohormonal changes that worsen heart failure. Effective treatment requires medications like ACE inhibitors, beta blockers, or ARNI therapy.